Regeneron

Today we’re reflecting on the meaningful celebration of Hispanic Heritage Month organized by our Juntos employee resource group (ERG) over the past month. From cultural experiences - like dance workshops and cooking classes - to informative sessions - like a Hispanic/Latinx-focused health equity seminar and best-in-class scientific presentations - Juntos’ events offered something for everyone, all in the spirit of building connection and community. Learn more about how our ERGs like Juntos contribute to a culture of inclusion that supports innovation: https://bit.ly/3U8w9XA

Our ninth annual Day for Doing Good (D4DG) week of global volunteerism kicks off later this week. Learn about a few of our colleagues who are stepping up as project leaders to champion causes they care about: https://bit.ly/4nSbnJ3   Follow along to see how our colleagues make a difference and share your own volunteer stories with #RegeneronD4DG. 

In Vivo recently featured Alison Fenney, Executive Director, Strategic Partnerships at RGC, in its story “Beyond Data Sharing: How Biopharma Is Rewriting the Rules of Collaboration”.    Alison discusses how RGC builds global trust through responsible data stewardship—ensuring transparency with partners, safeguarding data, and maintaining integrity throughout the data lifecycle. Read more: https://bit.ly/3KHz6gB

Regeneron Genetics Center (RGC) is advancing the frontiers of multi-omics with new data in metabolomics.  Layering multiple types of information on one disease enables us to deepen our understanding, and ultimately, inform our therapeutic approach. From rare variant discovery to insights into cardiometabolic health and cancer risk, our scientists are spotlighting cutting edge multi-omics research.  Learn more about presentations at #ASHG25: https://bit.ly/42MicmY

As part of our continued efforts to respond to the Ebola outbreak in the Democratic Republic of Congo, Regeneron is covering air freight and logistics to enable Afya Foundation’s delivery of over 40 pallets of personal protective equipment (PPE) to frontline healthcare workers. The DRC is facing acute shortages of PPE, and without adequate protection, health systems risk collapse. Available PPE enables continuity of care, early containment, and protection for brave healthcare providers. We’re proud to support this effort, which follows our donation of up to 500 doses of our monoclonal antibody treatment to the World Health Organization for use in countries at high-risk of Ebola outbreaks, including the DRC.

📅 It’s mid-October, which means our colleagues around the world are getting ready to take part in #RegeneronD4DG — a beloved annual tradition that personifies our ethos of Doing Well by Doing Good. During D4DG, our colleagues blend their personal passions with volunteer projects, working together to support and strengthen the communities where we live and work while fostering meaningful connections with one another.   Follow along to see how our colleagues make a difference and share your own volunteer stories with #RegeneronD4DG. 

How do you explain a cutting-edge genomics analytics tool like REGENIE? With building blocks, magnets, and help from a 7-year-old science simplifier named Matilda. 🧲🧬 In this #TechTrailblazers episode, Joelle Mbatchou, PhD, Statistical Geneticist breaks down how REGENIE helps researchers worldwide uncover potential therapeutic targets faster and smarter. Because science should be powerful and easy to understand. Watch the full video: https://bit.ly/4obY9Xo

Clinical trials don’t just help move medicine forward—they reflect what’s possible when science and human dedication come together.      Dr. Dipenkumar Modi became a clinical trial investigator to be a part of that progress: “My legacy is defined by the meaningful contributions I am making to help advance science.”      Learn how clinical trials help bridge today’s limitations and tomorrow’s breakthroughs.    🔗 https://bit.ly/3JiOTlj      #WhatsYourLegacy  

👀 Any idea what you’re looking at?  

The U.S. FDA approved our medicine to treat children aged one to less than five years old with #HoFH (homozygous familial hypercholesterolemia), an ultra-rare inherited condition that results in extremely high levels of bad cholesterol, or LDL-C.  This medicine expands treatment options for some of the youngest people with HoFH, addressing a critical need within the community. The approval reinforces the importance of early diagnosis and care to help this vulnerable patient population.  Learn more: https://bit.ly/3IHu3Mg